Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

United States Revenue

United States Revenue % Chg.

United States Revenue Common Size

Europe Revenue

Europe Revenue % Chg.

Europe Revenue Common Size

Japan Revenue

Japan Revenue % Chg.

Japan Revenue Common Size

Rest of World Revenue

Rest of World Revenue % Chg.

Rest of World Revenue Common Size

Total Revenue by Geography

Total Revenue by Geography Common Size

Total Revenue by Geography % Chg.

Revenue by Geography

Transcatheter Aortic Valve Replacement Revenue

Transcatheter Aortic Valve Replacement Revenue % Chg.

Transcatheter Aortic Valve Replacement Revenue Common Size

Transcatheter Mitral and Tricuspid Therapies Revenue

Transcatheter Mitral and Tricuspid Therapies Revenue % Chg.

Transcatheter Mitral and Tricuspid Therapies Revenue Common Size

Surgical Structural Heart Revenue

Surgical Structural Heart Revenue % Chg.

Surgical Structural Heart Revenue Common Size

Critical Care Revenue

Critical Care Revenue % Chg.

Critical Care Revenue Common Size

Total Revenue

Total Revenue Common Size

Total Revenue % Chg.

Revenue	LTM	Dec '24	Dec '23
Transcatheter Aortic Valve Replacement Revenue	4,363.7	4,106.1	3,879.8
Transcatheter Mitral and Tricuspid Therapies Revenue	500	352.1	197.6
Surgical Structural Heart Revenue	1,020.1	981.3	932.6
Critical Care Revenue	—	—	—
Total Revenue	5,883.8	5,439.5	5,010

Revenue by Geography	LTM	Dec '24	Dec '23
United States Revenue	3,449	3,206	2,947.9
Europe Revenue	1,451.6	1,321.7	1,180.2
Japan Revenue	353.1	339.8	350.8
Rest of World Revenue	630.1	572	531.1
Total Revenue by Geography	5,883.8	5,439.5	5,010